Home › Funds › 683 Capital Management, LLC › TGTX
683 Capital Management, LLC position in TGTX
TG THERAPEUTICS · Health Care
683 Capital Management, LLC reported holding 389,081 shares of TGTX (TG THERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$21.4M, representing 1.14% of its reported portfolio and ranking #21 among its reported holdings. 683 Capital Management, LLC has disclosed TGTX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How 683 Capital Management, LLC's TGTX position evolved
683 Capital Management, LLC first disclosed a stake in TGTX in Q3 2023 at 1,350,000 shares (US$11.3M). The position peaked in Q3 2024 at 1,135,000 shares, worth US$26.5M. Across 11 filings, 683 Capital Management, LLC increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 389,081 shares valued at US$21.4M — a reduction of -200,919 shares quarter over quarter.. Notable position changes include a 100% trim in Q4 2023 (shares fell 11% over the following quarter), a 32400% increase in Q1 2024 (shares rose 17% over the following quarter), a 64% increase in Q1 2026 (shares rose 65% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.35M | $11.29M | New |
| Q4 2023 | 5.00K | $85.40K | Reduce |
| Q1 2024 | 1.62M | $24.72M | Add |
| Q2 2024 | 1.40M | $24.91M | Reduce |
| Q3 2024 | 1.14M | $26.55M | Reduce |
| Q4 2024 | 697.00K | $20.98M | Reduce |
| Q1 2025 | 295.00K | $11.63M | Reduce |
| Q3 2025 | 325.00K | $11.74M | New |
| Q4 2025 | 360.00K | $10.73M | Add |
| Q1 2026 | 590.00K | $19.60M | Add |
| Q2 2026 | 389.08K | $21.38M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TGTX and 13F data
TGTX (TG THERAPEUTICS) is a Health Care company. 52 other funds we track also report a position in TGTX — the largest reported positions include Soleus Capital Management, L.P. (US$160.9M), CONGRESS ASSET MANAGEMENT CO (US$145.4M), Penn Capital Management Company, LLC (US$29.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TGTX
- Soleus Capital Management, L.P. 2.93M sh · $160.86M · Q2 2026
- CONGRESS ASSET MANAGEMENT CO 2.61M sh · $145.39M · Q3 2026
- Penn Capital Management Company, LLC 536.07K sh · $29.51M · Q2 2026
- Opaleye Management Inc. 535.00K sh · $29.39M · Q2 2026
- Occam Crest Management LP 425.00K sh · $22.73M · Q2 2026
More on 683 Capital Management, LLC
FAQ
How long has 683 Capital Management, LLC held TGTX?
683 Capital Management, LLC has disclosed TGTX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.
What is 683 Capital Management, LLC's current position in TGTX?
As of Q2 2026, 683 Capital Management, LLC holds 389.08K shares of TGTX (TG THERAPEUTICS), valued at $21.38M, representing 1.14% of its reported portfolio and ranking #21.
Has 683 Capital Management, LLC been buying or selling TGTX?
In the latest 13F filing (Q2 2026), 683 Capital Management, LLC reduced its position in TGTX. The position peaked in Q3 2024 at 1.14M shares.
Which other funds hold TGTX?
Other major institutional holders of TGTX include Soleus Capital Management, L.P., CONGRESS ASSET MANAGEMENT CO, Penn Capital Management Company, LLC, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.